CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Cencora delivered solid Q2 FY 26 results with adjusted EPS of $4.75 (+7.5% Y/Y), beating consensus by $0.02. Revenue growth of 3.8% to $78.4B represented a deceleration from recent quarterly trends. U.S. Healthcare Solutions (88% of revenue) posted 2.9% growth to $68.8B driven by specialty product volumes, GLP-1 class drug sales, and contributions from the OneOncology acquisition, with operating margin expanding to 1.45% from 1.41%, while International Healthcare Solutions showed strong 13.0% growth (7.2% constant currency) to $7.6B primarily from European distribution business expansion with margin improvement to 2.32%. COR raised full-year adjusted EPS guidance to $17.65-$17.90 from $17.45-$17.75, supported by resumption of share repurchases targeting $1B by year-end. We view the guidance raise and accelerated capital returns positively. COR maintained adjusted FCF guidance of approximately $3.0B for FY 26, supporting continued dividend growth and capital returns to shareholders in our view.